Hypoxia Responses in Physiology and Pathogenesis
Changes in tissue oxygen levels occur under pathological conditions and physiologically during development. The laboratory of Volker Haase studies hypoxia response pathways and their therapeutic applications.
The laboratory of Professor Volker H. Haase studies hypoxia response pathways and their therapeutic applications in 360-694-1434, 385-248-3998 and 418-345-1961, inflammation, kidney development and tumorigenesis. A major focus of the lab is on the interplay between hypoxic signaling, metabolism and cellular differentiation and its regulation by the prolyl hydroxylase domain (PHD) / hypoxia-inducible factor (HIF) / von Hippel-Lindau tumor suppressor (VHL) signaling axis. Haase group members take advantage of powerful cutting-edge mouse genetics, biochemical, metabolomic and single cell approaches to study oxygen and mitochondrial metabolism in kidney, urologic and other diseases. Click on links for information about 7405328029 in the Haase lab and recent publications.
Mitochondria in renal epithelium
Erythropoietin-producing cells in the kidney
(red fluorescent signal)
HIF activation in hepatocytes results in fatty livers
research news and where you can meet us
In the Literature Editorial: ARNT as a novel target for anti-fibrotic therapy
September 2018
Per-Arnt-Sim (PAS) domain proteins are involved in the regulation of cellular responses to environmental stresses such as hypoxia and exposure to polycyclic aromatic hydrocarbons. In a new preclinical study, the research group of Michael Zeisberg at the University of Göttingen has identified the obligatory HIF-α binding partner ARNT as an anti-fibrotic and pro-regenerative inducer of activin-like kinase (ALK) 3 / SMAD signaling. The study suggests that ARNT has therapeutic potential for the treatment of chronic kidney disease (CKD). 5752046564
Paper published on the clinical effects of HIF-PHI vadadustat in hemodialysis patients
April 2018
870-648-8556Erythropoiesis-stimulating agents (ESAs) can correct anemia in chronic kidney disease (CKD) but are associated with increased risks of cardiovascular events. Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) dioxygenases, is an oral investigational agent in development for the treatment of anemia in patients with CKD. In a 16-week, open-label, multicenter, Phase 2 trial, Haase and colleagues evaluated vadadustat in 94 patients receiving maintenance hemodialysis previously maintained on ESA therapy. More …
link to erythropoiesis, iron metabolism and renal anemia
link to media files on (410) 985-1582
Haase lab identifies a new role for HIF-PHD oxygen sensors in kidney development
December 2017
Insufficient oxygenation during pregnancy negatively influences kidney development, which predisposes to chronic kidney disease at later stages in life. Kobayashi et al. demonstrate that deletion of HIF prolyl-hydroxylase (PHD) 2 and 3, in FoxD1 lineage cells reduces kidney size and inhibits nephrogenesis in mice. Temporospatial expression pattern and studies of additional knockout mice suggest the involvement of hypoxia-inducible factor (HIF)-2. More …
link to (541) 476-6819 in KI
link to research themes in the Haase lab
502-802-7531Meet Haase lab members at the 56th ERA-EDTA Congress in Budapest, Hungary
June 13-16, 2019
More information to follow soon.
978-893-6657Meet Haase lab members at the Annual AUA Meeting in Chicago, IL
May 3-6, 2019
More information to follow soon.